M2 mediated contractions of human bladder from organ donors is associated with an increase in urothelial muscarinic receptors

Neurourology and Urodynamics

Volumn 26, Issue 1, 2007, Pages 63-70

  Braverman, Alan S ^a   Lebed, Brett ^a   Linder, Mitchell ^a   Ruggieri Sr , Michael R ^a,b  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Temple University   (United States)

Author keywords

Bladder contraction; Bladder mucosa; Immunoprecipitation; Urothelium

Indexed keywords

CARBACHOL; DARIFENACIN; METHOCTRAMINE; MUSCARINIC M2 RECEPTOR; MUSCARINIC M3 RECEPTOR; MUSCARINIC RECEPTOR; BENZOFURAN DERIVATIVE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CHOLINERGIC RECEPTOR STIMULATING AGENT; DIAMINE; MUSCARINIC RECEPTOR BLOCKING AGENT; PYRROLIDINE DERIVATIVE;

ADOLESCENT; ADULT; AGED; ANIMAL TISSUE; BLADDER CONTRACTION; BLADDER MUSCLE; CHILD; CLINICAL ARTICLE; CONFERENCE PAPER; DETRUSOR MUSCLE; DRUG RECEPTOR BINDING; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOPRECIPITATION; LIGAND BINDING; MALE; NONHUMAN; ORGAN DONOR; RECEPTOR DENSITY; SWINE; UROTHELIUM; ANIMAL; ARTICLE; BLADDER; DONOR; DRUG ANTAGONISM; DRUG EFFECT; DRUG POTENTIATION; IN VITRO STUDY; INNERVATION; MIDDLE AGED; MUSCLE CONTRACTION; PHYSIOLOGY; PRESCHOOL CHILD; SMOOTH MUSCLE;

ADOLESCENT; ADULT; AGED; ANIMALS; BENZOFURANS; CARBACHOL; CHILD; CHILD, PRESCHOOL; CHOLINERGIC AGONISTS; DIAMINES; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCARINIC ANTAGONISTS; MUSCLE CONTRACTION; MUSCLE, SMOOTH; PARASYMPATHOLYTICS; PYRROLIDINES; RECEPTOR, MUSCARINIC M2; SUS SCROFA; TISSUE DONORS; URINARY BLADDER; UROTHELIUM;

EID: 33846637760     PISSN: 07332467     EISSN: 15206777     Source Type: Journal    
DOI: 10.1002/nau.20378     Document Type: Conference Paper

References (43)

1. Appell RA, Sand P, Dmochowski R, et al. 2001. Prospective randomized controlled trial of extended-release oxybutynin chloride and tolterodine tartrate in the treatment of overactive bladder: Results of the OBJECT Study [see comment]. Mayo Clinic Proc 76:358-63.
2. Birder LA. 2005. More than just a barrier: Urothelium as a drug target for urinary bladder pain [Review] [78 refs]. Am J Physiol-Renal Physiol 289:F489-95.
3. Braverman AS, Ruggieri MR, Sr. 2003. Hypertrophy changes the muscarinic receptor subtype mediating bladder contraction from M3 toward M2. Am J Physiol-Regul Integr Comp Physiol 285:R701-08.
4. Braverman A, Legos J, Young W, et al. 1999. M2 receptors in genito-urinary smooth muscle pathology. Life Sci 64:429-36.
5. Braverman AS, Tallarida RJ, Ruggieri MR, Sr. 2002. Interaction between muscarinic receptor subtype signal transduction pathways mediating bladder contraction. Am J Physiol-Regul Integr Comp Physiol 283: R663-68.
6. Caulfield MP. 1993. Muscarinic receptors-characterization, coupling and function. Pharmacol Ther 58:319-79.
7. Caulfield MP, Birdsall NJ. 1998. International union of pharmacology. XVII. Classification of muscarinic acetylcholine receptors [Review] [146 refs]. Pharmacol Rev 50:279-90.
8. Cawley TA, Jr., Shickley TJ, Ruggieri MR, et al. 1993. Effect of chronic neuroleptic treatment on central and peripheral muscarinic receptors. J Pharmacol Exp Ther 267:134-39.
9. Chaiyaprasithi B, Mang CF, Kilbinger H, et al. 2003. Inhibition of human detrusor contraction by a urothelium derived factor. J Urol 170:1897-900.
10. Chancellor MB, Appell RA, Sathyan G, et al. 2001. A comparison of the effects on saliva output of oxybutynin chloride and tolterodine tartrate [see comment]. Clin Ther 23:753-60.
11. Chapple CR, Martinez-Garcia R, Selvaggi L, et al., for the Ssg. 2005. A comparison of the efficacy and tolerability of solifenacin succinate and extended release tolterodine at treating overactive bladder syndrome: Results of the STAR trial. Eur Urol 48:464-70.
12. Chess-Williams R. 2002. Muscarinic receptors of the urinary bladder: Detrusor, urothelial and prejunctional. Auton Autacoid Pharmacol 22:133-45.
13. Chess-Williams R, Chapple CR, Yamanishi T, et al. 2001. The minor population of M3-receptors mediate contraction of human detrusor muscle in vitro. J Auton Pharmacol 21:243-48.
14. D'Agostino G, Bolognesi ML, Lucchelli A, et al. 2000. Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: Involvement of the M4 receptor subtype. Br J Pharmacol 129:493-500.
15. de Groat WC. 2004. The urothelium in overactive bladder: Passive bystander or active participant? Urology 64:7-11.
16. Diokno A, Sand P, Labasky R, et al. 2002. Long-term safety of extended-release oxybutynin chloride in a community-dwelling population of participants with overactive bladder: A one-year study. Int Urol Nephrol 34:43-9.
17. Drutz HP, Appell RA, Gleason D, et al. 1999. Clinical efficacy and safety of tolterodine compared to oxybutynin and placebo in patients with overactive bladder. Int Urogynecol J 10:283-89.
18. Ehlert FJ, Griffin MT, Abe DM, et al. 2005. The M2 muscarinic receptor mediates contraction through indirect mechanisms in mouse urinary bladder. J Pharmacol Exp Ther 313:368-78.
19. Emala CW, Aryana A, Levine MA, et al. 1995. Basenji-greyhound dog: Increased m2 muscarinic receptor expression in trachealis muscle. Am J Physiol 268:L935-40.
20. Fetscher C, Fleichman M, Schmidt M, et al. 2002. M(3) muscarinic receptors mediate contraction of human urinary bladder. Br J Pharmacol 136:641-43.
21. Gevaert T, Ost D, De Ridder D. 2006. Comparison study of autonomous activity in bladders from normal and paraplegic rats. Neurourol Urodyn 24:368-78.
22. Haab F, Stewart L, Dwyer P. 2004. Darifenacin, an M3 selective receptor antagonist, is an effective and well-tolerated once-daily treatment for overactive bladder [Review] [36 refs]. Eur Urol 45:420-29; discussion 429.
23. Halaska M, Ralph G, Wiedemann A, et al. 2003. Controlled, double-blind, multicentre clinical trial to investigate long-term tolerability and efficacy of trospium chloride in patients with detrusor instability. World J Urol 20:392-99.
24. Hawthorn MH, Chapple CR, Cock M, et al. 2000. Urothelium-derived inhibitory factor(s) influences on detrusor muscle contractility in vitro. Br J Pharmacol 129:416-19.
25. Hegde SS. 2006. Muscarinic receptors in the bladder: From basic research to therapeutics. Br J Pharmacol 147:580-7.
26. Luthin GR, Harkness J, Artymyshyn RP, et al. 1988. Antibodies to a synthetic peptide can be used to distinguish between muscarinic acetylcholine receptor binding sites in brain and heart. Mol Pharmacol 34:327-33.
27. MacDiarmid SA, Anderson RU, Armstrong RB, et al. 2005. Efficacy and safety of extended release oxybutynin for the treatment of urge incontinence: An analysis of data from 3 flexible dosing studies. J Urol 174:1301-05; discussion 1305.
28. Mansfield KJ, Liu L, Mitchelson FJ, et al. 2005. Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: Changes in ageing. Br J Pharmacol 144:1089-99.
29. Miyamae K, Yoshida M, Murakami S, et al. 2003. Pharmacological effects of darifenacin on human isolated urinary bladder. Pharmacology 69:205-11.
30. Pontari MA, Luthin GR, Braverman AS, et al. 1998. Characterization of muscarinic cholinergic receptor subtypes in rat prostate. J Recept Signal Transduct Res 18:151-66.
31. Pontari MA, Braverman AS, Ruggieri MR, Sr. 2004. The M2 muscarinic receptor mediates in vitro bladder contractions from patients with neurogenic bladder dysfunction. Am J Physiol-Regul Integr Comp Physiol 286:R874-80.
32. Rovner ES, Wein AJ. 2002. Once-daily, extended-release formulations of antimuscarinic agents in the treatment of overactive bladder: A review [Review] [59 refs]. EurUrol 41:6-14.
33. Ruggieri MR, Sr., Braverman AS. 2006. Regulation of bladder muscarinic receptor subtypes by experimental pathologies. Auton Autacoid Pharmacol 26:311-26.
34. Ruggieri MR, Colton MD, Wang P, et al. 1995. Human prostate muscarinic receptor subtypes. J Pharmacol Exp Ther 274:976-82.
35. Schneider T, Fetscher C, Krege S, et al. 2004a. Signal transduction underlying carbachol-induced contraction of human urinary bladder. J Pharmacol Exp Ther 309:1148-53.
36. Schneider T, Hein P, Michel MC. 2004b. Signal transduction underlying carbachol-induced contraction of rat urinary bladder. I. Phospholipases and Ca2+ sources. J Pharmacol Exp Ther 308:47-53.
37. Siami P, Seidman LS, Lama D. 2002. A multicenter, prospective, open-label study of tolterodine extended-release 4 mg for overactive bladder: The speed of onset of therapeutic assessment trial (STAT). Clin Ther 24:616-28.
38. Sussman D, Garely A. 2002. Treatment of overactive bladder with once-daily extended-release tolterodine or oxybutynin: The antimuscarinic clinical effectiveness trial (ACET) [see comment]. Curr Med Res Opin 18:177-84.
39. Waldeck K, Larsson B, Andersson KE. 1997. Comparison of oxybutynin and its active metabolite, N-desethyl-oxybutynin, in the human detrusor and parotid gland. J Urol 157:1093-97.
40. Wang P, Luthin GR, Ruggieri MR. 1995. Muscarinic acetylcholine receptor subtypes mediating urinary bladder contractility and coupling to GTP binding proteins. J Pharmacol Exp Ther 273:959-66.
41. Yamanishi T, Chapple CR, Yasuda K, et al. 2000. The role of M(2)-muscarinic receptors in mediating contraction of the pig urinary bladder in vitro. Br J Pharmacol 131:1482-88.
42. Yasuda RP, Ciesla W, Flores LR, et al. 1993. Development of antisera selective for m4 and m5 muscarinic cholinergic receptors: Distribution of m4 and m5 receptors in rat brain. Mol Pharmacol 43:149-57.
43. Yono M, Yoshida M, Wada Y, et al. 1999. Pharmacological effects of tolterodine on human isolated urinary bladder. Eur J Pharmacol 368:223-30.